National 09 November 2026
NPPA Caps Trade Margins on 137 Anti-Cancer Drugs to Improve Affordability
Why in the News?
The National Pharmaceutical Pricing Authority (**NPPA**) has capped trade margins on the Maximum Retail Price (MRP) of **137 anti-cancer drugs** based on recommendations by an Expert Committee constituted by the Directorate General of Health Services (DGHS).
Key Features / Major Points:
- Trade Margin Rationalisation (TMR):
- Trade margins for non-scheduled anti-cancer medications have been capped at a maximum of **30%**.
- Substantial Price Reductions:
- 76 pharmaceutical companies have reported revised MRPs covering 1,225 anti-cancer formulations.
- Price reductions have been reported across 1,031 formulations, with **over 600 brands registering a price drop of more than 50%**, and the **highest reduction touching 96.45%**.
- Consumer Savings:
- The price rationalisation is estimated to result in annual savings of **₹3,502.31 crore** for consumers.
- Future-Proofing:
- Out of the 137 identified drugs, 10–15 are yet to be launched in India; however, TMR will automatically apply to them upon their launch.
---
Static GK Facts:
- National Pharmaceutical Pricing Authority (NPPA):
- Established: **August 29, 1997** | Headquarters: **New Delhi**.
- Parent Ministry: Department of Pharmaceuticals, **Ministry of Chemicals and Fertilizers**.
- Regulatory Framework:
- Implemented under the provisions of the **Drugs (Prices Control) Order, 2013 (DPCO)**.
One-Liner Quiz (All Competitive Exams):
Q: Which statutory body capped trade margins on 137 anti-cancer drugs at 30%?
A: National Pharmaceutical Pricing Authority (NPPA)
Q: What is the estimated annual consumer savings expected from the NPPA's trade margin cap on anti-cancer drugs?
A: ₹3,502.31 crore
Q: Under which Union Ministry does the NPPA operate?
A: Ministry of Chemicals and Fertilizers
#NPPA #AntiCancerDrugs #TradeMarginRationalization #Healthcare #PharmaPricing #CurrentAffairs #StaticGK